Skip to main content
. 2022 Apr 12;15:3977–3989. doi: 10.2147/IJGM.S352536

Figure 2.

Figure 2

Waterfall plot for the best percentage change in target lesion of the 32 patients with patients with previously treated epithelial ovarian cancer who were treated with anlotinib combined with PD-1 blockades administration.